Adverse Events and Associated Economic Burden of COVID-19 Vaccination in Queensland, Australia: Findings from the Cross-Sectional QoVAX-Statewide Study
Open Access
Abstract
Background/Objectives: The economic impact of adverse events following COVID-19 immunisation (AEFIs) in Australia is underexplored. This study aimed to assess the economic burden of AEFIs on both healthcare systems and societal productivity. Methods: A cross-sectional survey was conducted in Queensland residents aged ≥18 years who had received at least one dose of a COVID-19 vaccine in the preceding 12 months. Overall, 6964 participants were recruited from July to September 2022 via email and broad social media campaigns. The survey collected data on the incidence, type and duration of AEFIs; healthcare utilisation; and work-related absenteeism. Healthcare costs were estimated using national healthcare reimbursement data, and productivity costs were estimated using Australian Bureau of Statistics Average Weekly Earnings. Results: Of the 6797 eligible respondents (predominantly female [62%]; median age: 52 years), AEFIs were reported by 53.4%, 44.1%, 40.7%, and 40.9% following doses 1 to 4, respectively. Pain and tenderness were predominant local AEFIs, while tiredness and headaches were the most frequent systemic AEFIs, generally resolving within three days. Relatively few participants reporting AEFIs consulted medical professionals: 7.0%, 7.3%, 5.1%, and 1.9% following each dose, respectively. The mean healthcare cost per person reporting AEFIs was AUD 24, AUD 88, AUD 22, and AUD 4 following each respective dose. Work absenteeism was recorded in 16.5%, 18.2%, 15.2%, and 11.2% following each dose with mean absenteeism days per person of 4.7, 7.4, 3.6 and 2.1, respectively, and mean productivity costs per person reporting AEFIs amounting to AUD 1494, AUD 2388, AUD 1136, and AUD 690, respectively. Conclusions: Participants reported mostly mild AEFIs with only a small proportion of individuals seeking medical services. Productivity costs attributable to these AEFIs exceeded direct healthcare expenses incurred.Keywords
All Related Versions
Funding Information
- Metro North Health from Queensland Health (QH)
- National Partnership on COVID-19 Response
This publication has 28 references indexed in Scilit:
- Australian preferences for influenza vaccine attributes and cost: A discrete choice experimentHuman Vaccines & Immunotherapeutics, 2024
- Safety and efficacy of COVID‐19 vaccines: A systematic review and meta‐analysis of controlled and randomized clinical trialsReviews in Medical Virology, 2023
- Inability to work following COVID-19 vaccination–a relevant aspect for future booster vaccinationsPublic Health, 2023
- Safety and effectiveness of vaccines against COVID-19 in children aged 5–11 years: a systematic review and meta-analysisThe Lancet Child & Adolescent Health, 2023
- The Use of a Discrete Choice Experiment Including Both Duration and Dead for the Development of an EQ-5D-5L Value Set for AustraliaPharmacoEconomics, 2023
- Adverse events following COVID-19 vaccination: A systematic review and meta-analysisInternational Immunopharmacology, 2022
- Adverse Events Reported From COVID-19 Vaccine Trials: A Systematic ReviewIndian Journal of Clinical Biochemistry, 2021
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 VaccineNew England Journal of Medicine, 2020
- Efficacy and safety of COVID-19 vaccines in older peopleAge and Ageing, 2020
- Productivity Costs in Economic Evaluations: Past, Present, FuturePharmacoEconomics, 2013